Brief: Marksans Pharma Announces UK MHRA Approval For Fluoxetine 20Mg/5Ml Oral Solution
23/01/2023 07:37
Jan 23 (Reuters) - Marksans Pharma Ltd MARK.NS :
* MARKSANS PHARMA LTD - ANNOUNCES UK MHRA APPROVAL FOR FLUOXETINE 20MG/5ML
ORAL
SOLUTION
* MARKSANS PHARMA LTD - PRODUCT WILL BE MANUFACTURED AT PLANT OF BELL, SONS
& CO
LOCATED AT SOUTHPORT, UK.
* MARKSANS PHARMA LTD - UK MHRA HAS GRANTED MARKET AUTHORISATION TO UNIT,
RELONCHEM
Source text for Eikon: ID:nBSEb57Tz6
Further company coverage: MARK.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Marksans Pharma
See all newsIndia's Marksans Pharma jumps to over 18-month high after more than doubling quarterly profit
Brief: Marksans Pharma Ltd To Acquire 100% Of Netherlands-Based Qliniq B.V
India's Marksans Pharma jumps to 10-month high after Q4 profit rise
Brief: Marksans Pharma March-Quarter Consol Net Profit 1.48 Billion Rupees
Brief: Marksans Pharma Ltd Receives USFDA Approval For Benzonatate Capsules USP, 100 Mg & 200 Mg